Navigation Links
Cambridge Laboratories Announces Approval of Tetrabenazine in Spain
Date:12/8/2008

DUBLIN and NEWCASTLE, England, December 8 /PRNewswire/ --

- Marketing Partner UCB Expects to Receive Completed Price and Reimbursement Approval for Tetrabenazine in H1 2009

- Exclusive Distribution Rights Granted in Finland (MediFront) and Taiwan (Giddi Pharma); Distribution Contracts Renewed in Australia and New Zealand

Cambridge Laboratories Limited ("Cambridge" or "the Company"), the privately-owned specialty pharmaceutical company, today announces that its flagship product Tetrabenazine, (known as NITOMAN(R) in Germany and other key European territories and XENAZINE(R) in the UK, US and other markets) has received marketing approval in Spain from the Agencia Espanola de Medicamentos y Productos Sanitarios.

The Company also announces that it has recently signed distribution agreements for Tetrabenazine in Finland and Taiwan, and renewed existing arrangements in Australia and New Zealand.

Tetrabenazine will be marketed as NITOMAN(R) in Spain by Cambridge's marketing partner UCB upon successful completion of all related procedures. It has been approved for the treatment of movement disorders associated with Huntington's disease, a condition for which there is major unmet medical need.

Cambridge has recently renegotiated its agreements with UCB in Spain and Portugal, giving UCB ten year exclusive marketing rights to Tetrabenazine in Spain. UCB, a global biopharmaceutical company, is focused on severe diseases in three therapeutic areas - inflammation, oncology and neurology. The renegotiated terms follow UCB's acquisition of Celltech, Cambridge's former partner in Spain and Portugal, and the more recent merger of UCB with Schwarz Pharma.

UCB is currently in the process of applying for price and reimbursement in Spain and expects to have this procedure completed in the first half of 2009.

Mark Evans, CEO of Cambridge, said: "The granting of a
'/>"/>

SOURCE Cambridge Laboratories Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters
2. IBT Laboratories Expands its Menu of Tests for Immune Deficiency
3. Roxane Laboratories, Inc. Updated Launch of Calcium Acetate Capsules, 667mg
4. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
5. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
6. Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
7. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
8. Northfield Laboratories Inc. Presentation at FDA/NIH Workshop on Hemoglobin-Based Oxygen Carriers
9. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
10. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
11. Romark Laboratories Raises $18 Million in Institutional Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... The issue: Mylan Pharmaceuticals ULC Canada, in consultation with Health ... 0.4 mg/metered dose due to the product missing the "dip ... A missing "dip tube" could pose a potential problem ... may lead patients to believe they are receiving the nitroglycerin, ... receiving nitroglycerin could place them at risk for either a ...
(Date:9/19/2014)... , Sept. 19, 2014 Medical science ... relationships with key opinion leaders (KOLs) who can ... Despite the critical nature of the MSL function, ... including altering the landscape for creating and maintaining ... to research, the oversight responsibility for the MSL ...
(Date:9/19/2014)... , Sept. 19, 2014 Harwood Feffer LLP ... board of directors of PDL BioPharma, Inc. ("PDL" or ... the board has breached its fiduciary duties to shareholders ... September 16, 2014, the Company disclosed: "On September 11, ... accounting firm, Ernst & Young LLP ("EY"), that it ...
Breaking Medicine Technology:Advisory - Mylan Pharmaceuticals recalling nitroglycerin spray due to defective pump 2Role of Medical Science Liaisons Shifting in Healthcare Industry 2Harwood Feffer LLP Announces Investigation of PDL BioPharma, Inc. 2
... 2011 ,   EP ... of the Year Award at the European Mediscience,Awards, sponsored ... award, which honours clear and concise commentary in the,pharma ... research houses or specialist websites dedicated to,providing sharp, perceptive ...
... 24, 2011 New Phase 2 clinical trial data ... of Medicine show that patients with moderate to ... bardoxolone methyl for 52 weeks experienced a sustained improvement ... by estimated glomerular filtration rate (eGFR). The data were ...
Cached Medicine Technology:EP Vantage Wins Commentator of the Year Award at European Mediscience Awards 2011 2EP Vantage Wins Commentator of the Year Award at European Mediscience Awards 2011 3New Phase 2 Data Published in New England Journal of Medicine Show Bardoxolone Methyl Sustained Improvement in Measure of Kidney Function (eGFR) Over 52 Weeks in Patients With Moderate to Severe Chronic Kidney Disease and Type 2 Diabetes 2New Phase 2 Data Published in New England Journal of Medicine Show Bardoxolone Methyl Sustained Improvement in Measure of Kidney Function (eGFR) Over 52 Weeks in Patients With Moderate to Severe Chronic Kidney Disease and Type 2 Diabetes 3New Phase 2 Data Published in New England Journal of Medicine Show Bardoxolone Methyl Sustained Improvement in Measure of Kidney Function (eGFR) Over 52 Weeks in Patients With Moderate to Severe Chronic Kidney Disease and Type 2 Diabetes 4
(Date:9/21/2014)... Colorado (PRWEB) September 21, 2014 High ... ten teams of disabled and able-bodied athletes rafted the ... completed a ropes course in pursuit of outdoor adventure. ... from national non-profit World T.E.A.M. Sports, disabilities proved to ... who successfully completed the three stage event. , Each ...
(Date:9/21/2014)... York, NY (PRWEB) September 21, 2014 ... http://www.thegranuflolawsuit.com/ ) have been added over the past ... claims that allege serious cardiovascular injuries caused by ... A Case List updated on September 15th shows ... in the U.S. District Court, District of Massachusetts. ...
(Date:9/21/2014)... An experienced review website in the global market, ... and announced that FatCow ( http://www.top10bestseohosting.com/go/FatCow.com/ ), GoDaddy and ... There has been a boom in websites in recent ... increase in the number of web hosting companies that ... prices. VPS (Virtual Private Server) is the method of ...
(Date:9/21/2014)... 21, 2014 “Cluster headaches are sometimes ... and difficult to resolve,” said Steve Young of Ew ... of a pain that is more intense.” , “It ... cluster headaches, or migraines, that medical research is pointing ... system,” he added. , Serotonin (5-HT, 5-hydroxytryptamine) is a ...
(Date:9/21/2014)... (PRWEB) September 21, 2014 Recently, BambooIndustry.com, ... a special offer for its bamboo panels ( http://www.bambooindustry.com/products/bamboo-panel/ ... the market; all of them are available at discounted ... , The company’s discounted bamboo panels are ... made of quality materials. Each of them is finely ...
Breaking Medicine News(10 mins):Health News:Disabled Athletes Excel at World T.E.A.M. Sports’ Adventure Team Challenge 2Health News:Disabled Athletes Excel at World T.E.A.M. Sports’ Adventure Team Challenge 3Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 2Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 3Health News:Federal GranuFlo Litigation Adds Dozens of Cases Alleging Serious Cardiovascular Injuries, Bernstein Liebhard LLP Reports 4Health News:Top10BestSEOHosting.com: FatCow, GoDaddy And Bluehost Are The Best VPS Hosting Suppliers 2Health News:Homeostasis: Equinox Serotonin (5HT) Headache Stories ~ New on the Bryan William Brickner Blog 2Health News:Discounted Bamboo Panels For Sale At BambooIndustry.com 2
... with the non-profit organization HopeLab to deliver innovative interventions ... young people with chronic illnesses . Their first joint ... and young adults with cancer by offering free of ... works. It gives young people with cancer a sense ...
... are more active and have less body fat than ... today at the 54th American College of Sports Medicine ... associated with higher levels of self-reported leisure-time physical activity ... weight, status, and neighborhood, environment, walkability, and income between ...
... lawmakers to set aside 30 billion dollars over five years ... proposal fell short of funds needed to battle the global ... would visit Africa in June to assess HIV/AIDS-fighting strategies in ... works and what does not in battling the deadly disease. ...
... holy city of Najaf on Friday after receiving treatment for ... of the most powerful parties in the parliament, spent nearly ... in the United States and treatment in Iran. ... there for a long time, after he finished his initial ...
... study has found that people can be encouraged to walk ... if they are given the right kind of help. ... the Scottish Physical Activity Research Collaboration (SPARColl), the study suggests ... of waysface to face advice or telephone support, using pedometers, ...
... found three new drugs that may help transform the ... thus giving hope for chronically infected patients. ,The ... Hiroyu Hatano, and Steven Deeks at San Francisco General ... new drugs are the HIV integrase inhibitors, R5 inhibitors, ...
Cached Medicine News:Health News:CIGNA HealthCare Teams With HopeLab to Help Blast Teen Cancer 2Health News:Dog Owners More Active, Leaner 2Health News:Bush Seeks Doubling of AIDS-fighting Funds 2Health News:Top Iraqi Shiite Leader Returns Home 2
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Stat Detection of Soluble Fibrin Monomer Complexes by the Hemagglutination Technique, 32 tests....
Batch Detection of Soluble Fibrin Monomer Complexes by the Hemagglutination Technique, 40 tests....
For use with catalog #0454....
Medicine Products: